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Abstract Differences in immunological response among
vaccine recipients are determined both by their genetic
differences and environmental factors. Knowledge of
genetic determinants of immunological response to a vac-
cine can be used to design a vaccine that circumvents
immunogenetic restrictions. The currently available vac-
cine for typhoid is a pure polysaccharide vaccine, immune
response to which is T-cell independent. Little is known
about whether genetic variation among vaccinees associ-
ates with variation in their antibody response to a poly-
saccharide vaccine. We conducted a study on 1,000
individuals resident in an area at high-risk for typhoid;
vaccinated them with the typhoid vaccine, measured their
antibody response to the vaccine, assayed [2,000 curated
SNPs chosen from 283 genes that are known to participate
in immune-response; and analyzed these data using a
strategy to (a) minimize the statistical problems associated
with testing of multiple hypotheses, and (b) internally
cross-validate inferences, using a half-sample design, with
little loss of statistical power. The first stage analysis, using
the first half-sample, identified 54 SNPs in 43 genes to be
significantly associated with immune response. In the
second-stage, these inferences were cross-validated using
the second half-sample. First-stage results of only 8 SNPs
(out of 54) in 7 genes (out of 43) were cross-validated. We
tested additional SNPs in these 7 genes, and found 8 more
SNPs to be significantly associated. Haplotypes con-
structed with these SNPs in these 7 genes also showed
significant association. These 7 genes are DEFB1, TLR1,
IL1RL1, CTLA4, MAPK8, CD86 and IL17D. The overall
picture that has emerged from this study is that (a) immune
response to polysaccharide antigens is qualitatively dif-
ferent from that to protein antigens, and (b) polymorphisms
in genes involved in polysaccharide recognition, signal
transduction, inhibition of T-cell proliferation, pro-inflam-
matory signaling and eventual production of antimicrobial
peptides are associated with antibody response to the
polysaccharide vaccine for typhoid.
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Introduction
Vaccination is one of the most effective public health tools
available to prevent and control the spread of infectious
diseases. However, the immune response induced by a
vaccine often varies between individuals, implying that a
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vaccine may not afford equal protection to all vaccinees.
The extent of variation in immune response has been
extensively studied for some vaccines. Primary failure, as
assessed by post-vaccination antibody levels, occurs in a
significant proportion of vaccinees; for example, 2–10%
for measles vaccine (Poland 1998; Poland et al. 1999), 5–
20% for hepatitis B vaccine (Milich and Leroux-Roels
2003; Zuckerman 1996), and 23–40% for typhoid vaccine
(Gupta et al. 2008; Sur et al. 2009).
Immunological mechanisms that are responsible for
protection against pathogens are often unknown. Measuring
clinical or microbiological protection conferred by a vac-
cine is best done by an artificial or a natural challenge,
which is rarely possible for ethical or practical reasons.
Vaccine responses are, therefore, commonly monitored by
measuring humoral antibody responses and sometimes cell-
mediated immune responses. Differences in antibody
response (AR) among vaccinees are partly due to environ-
mental factors, such as presence of maternal antibodies,
nutrition—in particular vitamin A deficiency—or other
infections, and partly due to genetic differences among the
vaccinees (Kimman et al. 2007; Poland and Jacobson 1998;
van Lovern et al. 2001). Twin studies have shown high and
statistically significant heritability for AR to measles (89%),
mumps (39%), rubella (46%), hepatitis B (61–77%), oral
polio (60%), tetanus (44–64%), diphtheria (49%), Hae-
mophilus influenzae type B [Hib] (51%), and other vaccines
(Kimman et al. 2007). Past linkage and association studies
conducted to study genomics of vaccine-induced AR have
revealed many interesting results. Polymorphic variants in
HLA genes have been found to be associated or linked with
AR to hepatitis B vaccine (Kruskall et al. 1992), influenza
vaccine (Gelder et al. 2002; Poland et al. 2008a), measles
vaccine (Poland 1998; Poland et al. 2008b), and BCG
tuberculosis vaccine (van Eden et al. 1983), among others.
However, non-MHC or non-HLA genes—IL1B, IL4R, IL6,
IL10 and TNF—have also been found to be independently
associated with response to hepatitis B vaccine (Wang et al.
2004). Interestingly, although measles, mumps and rubella
vaccines are all attenuated live vaccines that are adminis-
tered simultaneously, the responses induced by these vac-
cines are influenced differently by host genetics (Kimman
et al. 2007).
Vaccine immunogenicity is determined in part by the
chemical and physical nature of microbial antigens and
adjuvants, and also by the genetic make-up of vaccine
recipients (Pulendran et al. 2001). The rationale and value
of so-called ‘‘immunogenetic profiling’’ has been reviewed
(Jin and Wang 2003); knowledge of key immunogenetic
associations can be used to design a vaccine that circum-
vents immunogenetic restrictions. Most available vaccines
comprise microbial or added protein components. Insight
into the impact of genetic variation in vaccinees on AR has
also been obtained in some detail (Kimman et al. 2007) for
these vaccines.
Another class of vaccines is polysaccharide (PS) vac-
cines. PS vaccines are a unique type of inactivated subunit
vaccine composed of long chains of sugar molecules that
make up the surface capsule of certain bacteria, such as
Salmonella enterica serotype typhi (Salmonella typhi).
Currently, pure PS vaccines that are available include
pneumococcal, meningococcal and typhoid vaccines. The
essential feature of immune response to a pure PS vaccine
is that it is typically T-cell independent, which means that a
PS vaccine stimulates B-cells and non-cognate T-cells
without the assistance of cognate T cells (Vos et al. 2000;
Snapper 2006). Little is known about the role of genetic
variation in vaccinees on antibody response to PS vaccines.
Worldwide, typhoid fever affects 17 million people
annually, causing 600,000 deaths. It is caused by S. typhi
that is an obligate parasite and has no natural reservoir
outside of human. It is a gram-negative enteric bacillus and
multi-organ parasite that inhabits the lymphatic tissues of
small intestine, liver, spleen and bloodstream of infected
individuals. Over 100 strains of this parasite—that differ in
levels of virulence—have been isolated. It enters unin-
fected individuals via the fecal-oral route from infected
individuals. Therefore, individuals living under unhygienic
conditions—particularly in areas with open sewage, public
latrines and unclean drinking water—are most vulnerable
to typhoid infection and therefore in the greatest need of
vaccination. Salmonella typhimurium, that causes murine
typhoid, causes enteritis in humans characterized by self-
limited fever and diarrhea and, in some cases, dysentery;
symptoms that are rarely observed with S. typhi infection.
S. typhi has an outer capsule, Vi polysaccharide, that is
absent in S. typhimurium. Vi is a polymer of a-1,4-
galacturonic acid with an N-acetyl at position C-2 and
variable O-acetylation at C-3 (Szu et al. 1991). The
expression of this molecule correlates with virulence,
resistance to phagocytosis and resistance to complement-
mediated killing (Looney and Steigbigel 1986). Therefore,
the Vi PS has been used as a vaccine to protect individuals
from S. typhi infection. The objective of this study was to
quantify the extent of variation in antibody response to a
widely used Vi PS vaccine for typhoid and to discover
associations of polymorphisms in candidate genes of
vaccinees with antibody response. To our knowledge, this
is the first large-scale study on genomics of immune
response of a polysaccharide vaccine.
Materials and methods
Institutional ethical approvals were taken from all collab-
orating institutions before initiation of this study. Written
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informed consent was taken from each recruited partici-
pant. Approval of the Drug Controller General of India was
taken before administration of the vaccine to the study
participants. Dispatch of aliquots of serum samples col-
lected in this study to the collaborating laboratories in the
USA was approved by the Health Ministry Screening
Committee, Government of India.
Study participants
Individuals (n = 1,000), unrelated at least to the first-
cousin level, aged 12 years or older, inhabiting a socio-
economically depressed locality of Kolkata (formerly,
Calcutta), India, were recruited into this study. The resi-
dents belonged to two maritally isolated, religious groups,
Muslim and Hindu. The Muslims of this locality are mostly
religious converts, during the last 100 years, to Islam from
Hinduism. The individuals recruited into this study are
demographically (age-group, gender and religion) repre-
sentative of the entire locality, since care was taken to
recruit into age 9 gender 9 religion subgroups by a
probability proportional to size sampling scheme, with
population sizes of subgroups having been determined by
us through an initial complete-enumeration demographic
survey of the locality (comprising *9,950 individuals).
The following exclusionary criteria were used, based on
self-report, to recruit an individual into this study: that (a)
she/he had not had fever lasting for more than three con-
secutive days in the past 1 year, and (b) she was not
pregnant or lactating.
Vaccination and collection of blood samples
Each study participant was injected, intramuscularly, with
a 0.5 ml single-dose injectable vaccine, containing 25 lg
of the cell surface Vi polysaccharide extracted from S.
typhi Ty2 strain with the excipients sodium chloride,
sodium dihydrogen phosphate dihydrate, disodium phos-
phate dihydrate, phenol and water for injection. This vac-
cine is marketed in India as Typherix (manufactured by
GlaxoSmithKline, Inc.), and is widely used in Asia, Africa
and South America, and approved for use elsewhere,
including the European Union and the USA.
From each study participant, a blood sample was col-
lected immediately prior to vaccination. Blood samples
were also collected 3- and 28-days post-vaccination. Serum
and DNA were isolated from these samples, using standard
protocols and QiaGen columns.
Antibody response assay
A bead assay was performed using the Bio-Plex (Bio-Rad,
Hercules, CA) platform. The Vi PS antigen (supplied by
Fina Biosolutions, Rockville, MD, USA) was conjugated to
Bio Rad beads [COOH (028)] at a concentration
8.33 9 106 beads/ml in a total volume of 1.50 ml. About
50 ll of human serum was prepared at various dilutions in
human serum diluent (PBS, 1% W/V, 5% V/V goat serum,
0.05% Tween 20 V/V and 0.1% Kathon V/V). Day-0
serum was diluted 1:50, 1:400 and 1:3,200; Day-28 serum
diluted 1:200, 1:1,600 and 1:12,800 in human serum dilu-
ent before incubation with the Vi beads for 3 h. After
washing the beads, the bound human IgG was detected by
goat anti-human IgG-RPE (1:5,000 in human serum dilu-
ent) by incubation for 30 min. Following the final wash
steps, the beads were analyzed using the Bio-Plex instru-
ment. A pooled serum with a high anti-Vi IgG response
was used to create a standard curve that was assigned an
arbirtrary value of 200 ELISA units (EU) per ml. The
responses in the individual subjects were compared to the
standard curve to calculate anti-Vi IgG EU/ml in the Day-0
and Day-28 serum.
Candidate genes and SNPs
We selected 283 autosomal genes from immunological
pathways as candidates for this association study. SNPs
from these genes, including about 2 and 1 kb upstream and
downstream regions respectively, were chosen from the
HapMap database (http://www.hapmap.org). The choice of
SNPs was done using a statistical protocol that took into
account differences in LD patterns and allele frequencies in
the four HapMap populations. The statistical protocol
provided a ranking of the ‘‘potential informativeness’’ of
SNPs within each gene cataloged in the HapMap database,
from which a subset of maximally informative SNPs was
chosen. Further details are provided in Supplementary Text
S1 and the list of genes and SNPs are provided in Table 1
and Table S1. Genotyping was done using Sequenom
(55.7% of assayed SNPs) and Illumina (remaining 44.3%
of SNPs) platforms.
Statistical analysis
Antibody response (AR) to vaccination was measured as
the difference between 28-day post-vaccination and pre-
vaccination antibody levels (EU/ml). Values of AR were
log10-transformed (logAR) to induce normality to the fre-
quency distribution (Fig. 1) that is essential for using
standard parametric statistical methods for hypothesis
testing. Curation of genotype data included removal of (a)
loci with \90% call rate (8.9% of loci), (b) non-polymor-
phic loci with MAF \0.05 (24.7% of loci with call rate
[90%), (c) significantly deviant from HWE (4.2% of
polymorphic loci), (d) individuals with \75% of loci with
valid genotype calls, (e) individuals on whom antibody
HUGO J (2009) 3:17–30 19
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response could not be properly assayed (8 of 1,000 indi-
viduals), and (f) individuals showing cryptic relationships
([80% of loci with identical genotypes; 6 pairs of indi-
viduals satisfied this criterion, one individual from each
pair was randomly chosen for final analysis). After data-
curation, the final data set comprised genotypes of 984
individuals at 2,040 SNPs in 283 genes. Table 1 provides
the numbers of genes in different classes of molecular
function; the complete list of genes, SNPs selected from
these genes and other relevant information are provided in
Supplementary Table S1. Analysis of Variance (ANOVA)
was performed to test equality of mean values of logAR
among subgroups of vaccinees.
In conducting detailed statistical analyses of these data,
we deviated from ‘‘standard practice’’ (Wellcome Trust
Case Control Consortium 2007; Wellcome Trust Case
Control Consortium et al. 2007; Burgner et al. 2009; Sa-
mani et al. 2007; Baranska et al. 2008; Hennig et al. 2008)
and adopted a novel strategy. First, we did not classify the
vaccinees as ‘‘responders’’ and ‘‘non-responders’’, because
this would involve defining an arbitrary threshold on values
of antibody response to enable classification. Instead, we
Table 1 Numbers of genes in
various functional classes
included in this study
a GO (Gene Ontology) category
was obtained from gene2go file




GO categorya Molecular function No. of genes
GO:0004871 Signal transducer activity 86
GO:0005102 Receptor binding 44
GO:0001664 G-protein-coupled receptor binding 41
GO:0003676 Nucleic acid binding 21
GO:0000166 Nucleotide binding 19
GO:0001584 Rhodopsin-like receptor activity 16
GO:0005488 Binding 12
GO:0003824 Catalytic activity 7
GO:0004857 Enzyme inhibitor activity 6
GO:0003823 Antigen binding 3
GO:0001871 Pattern binding 3
GO:0001530 Lipopolysaccharide binding 2
GO:0008009 Chemokine activity 1
GO:0001948 Glycoprotein binding 1
GO:0015457 Auxiliary transport protein activity 1
GO:0032393 MHC class I receptor activity 1
GO:0003774 Motor activity 1
GO:0032395 MHC class II receptor activity 1
GO:0001532 Interleukin-21 receptor activity 1
GO:0005125 Cytokine activity 1
GO:0000287 Magnesium ion binding 1
GO:0005048 Signal sequence binding 1
GO:0005515 Protein binding 1
GO:0001540 Beta-amyloid binding 1
GO:0005215 Transporter activity 1









Defense response with MHC 1
Regulation of inflammatory responses 1
Putative immune function (Gene: HCG9;
lies within MHC class I region)
1
Total 283
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sorted the vaccinees by ascending order of their antibody
response and grouped the vaccinees into 5 pentile (20
percentile) groups. Second, we posited that if indeed an
allele at a locus was positively (or, negatively) associated
with antibody response, then its frequency among vacci-
nees should monotonically increase (or, decrease) from
those belonging to the lowest pentile group of antibody
response to those belonging to the highest pentile group. In
other words, the correlation coefficient between the minor
allele frequency (MAF) at the locus and mean AR of
vaccinees belonging to the pentile groups should be sta-
tistically significant. Third, in genomic studies involving a
large number of associated loci, correction for multiple
testing—especially if the loci are in significant linkage
disequilibrium (LD); that is, non-independent—remains a
major statistical problem (Conneely and Boehnke 2007;
Han et al. 2009). To circumvent this, for single-locus
association analysis, we reduced the number of tests by
selecting from each gene only the highly informative and
minimally associated SNPs, initially selecting the SNP
located at the most 50 end of the genomic region covered
for the gene. This strategy resulted in the choice of 469
SNPs from the genes under consideration. (The data on the
remaining loci were unused in the single-locus association
analysis, but were used for haplotype association analysis,
as explained later.) Fourth, cross-validation of findings of
an association study is often a problem. In addition, rep-
lication of a study similar to the present one is particularly
difficult because it entails the ethical choice of a population
in which individuals will benefit from the vaccination to be
provided. If the results are cross-validated in a different
population, then in the event of discordance of results with
the initial study it is difficult to ascertain whether popula-
tion differences were the cause of the observed discor-
dance. To avoid these vagaries, we generated an internal
cross-validation sample, by randomly splitting the 984
vaccinees into two half-samples, of *500 vaccinees in
each half-sample (with *100 vaccinees in each of the 5
pentile groups based on antibody response within each half
sample). While this strategy in which *500, instead of
*1,000, vaccinees are considered in the initial association
analysis results in some loss of statistical power, our sim-
ulation studies showed that the loss of power is only 3–
14% depending on the value of the correlation coefficient
between MAF and mean AR (results not shown). The
reason why the loss of statistical power is small is because
a sample of size *500 individuals (included in each half-
sample) is large. The small loss of statistical power is more
than offset by the gain in ability to cross-validate results
using the same population sample. The strategy is pre-
sented as a flow-chart in Fig. 2.
Test of significance of the correlation coefficient (r)
between MAF and mean antibody response was carried out
by a permutation test. Genotypes of individual vaccinees at
a locus were randomly permuted and the correlation
coefficient was computed in this permuted sample. This
procedure was repeated 1,000 times, to produce a histo-
gram of correlation coefficients under the null hypothesis
r = 0. This histogram was then used to compute the
P-value associated with the observed r at this locus. After
generating the P-values for all loci, the FDR procedure
(Benjamini and Hochberg 1995) was used to identify
statistically significant values of r at the 5% level of
significance.
We have also revalidated our inferences using the
‘standard’ procedure for association analysis, in which the
null hypothesis tested is that the mean logAR values among
the genotype classes are equal. This null hypothesis is tested
using ANOVA. All significant allelic associations with
logAR detected using the procedures described above were
also validated using genotype data using PLINK (Purcell
et al. 2007), Version 1.06 (http://www.pngu.mgh.
harvard.edu/~purcell/plink/).
To summarize our analytical strategy, we first tested—in
a random sample of 50% of our data (half-sample 1)—
whether the minor allele frequency at a locus increases (or
decreases) with increasing antibody response among
groups of vaccinees using correlation analysis, and data-
permutation and false discovery rate procedures for
assessing significance of the estimated correlation coeffi-
cient. For those SNPs that showed significant correlation,
we cross-validated the results in the remaining 50% of
our data (half-sample 2), using the same methodology
Fig. 1 Frequency distribution of log10-transformed values of anti-
body response among vaccinees
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(correlation, data-permutation and FDR analyses). Finally,
those SNPs for which inferences could be cross-validated,
we revalidated the inferences using a ‘standard’ approach
of testing equality of mean antibody-response among
genotypes by ANOVA.
Haplotypes were inferred using PHASE (Stephens et al.
2001; http://www.stat.washington.edu/stephens/phase.html
). Haplotype association analysis was performed using the
permutation algorithm described above for single SNP
markers.
Results
Demographic characteristics of vaccinees
Among the vaccinees (n = 984), 62.7% were Muslim and
37.3% were Hindu; 46.4% were male and 53.6% were
female. The mean age of the vaccinees was 33.7 ±
0.4 years. The male vaccinees (mean age = 34.7 years)
were, on the average, 2 years older than the female vacci-
nees (mean age = 32.7 years); this difference was statisti-
cally significant (P = 0.015). However, the mean ages of
the vaccinees did not differ significantly by religion (mean
age of Muslim and Hindu vaccinees were, respectively, 33.6
and 33.8 years; P = 0.76).
Pre- and post-vaccination antibody levels and antibody
response
Mean antibody levels (in EU/ml) prior to vaccination were
low, but were high on the 28th day post-vaccination
(Table 2). The antibody levels pre- or post-vaccination
were not significantly influenced by gender or religion.
Enormous variation in both pre- and 28-day post-vac-
cination antibody levels was observed. Table 3 provides
the descriptive statistics for the three variables (Days-0 and
Fig. 2 Flow-chart describing the strategy used in the conduct of statistical data analyses
Table 2 Pre- and post-vaccination antibody levels (EU/ml) among
vaccinees and their antibody response, classified by gender and
religion
Pre-vaccination Post-vaccination Antibody response
Gender
Male 1.77 ± 0.67 61.34 ± 5.10 59.57 ± 5.00
Female 1.38 ± 0.27 77.45 ± 7.03 76.06 ± 6.98
P-value* 0.185 0.088 0.100
Religion
Muslim 1.78 ± 0.53 77.48 ± 6.29 75.70 ± 6.23
Hindu 1.21 ± 0.23 57.34 ± 5.51 56.14 ± 5.42
P-value* 0.582 0.245 0.302
* P-values were calculated after log10-transformation of the data to
induce normality of the frequency distributions
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123
28 antibody levels, and antibody response (AR) = Differ-
ence between Day-28 and Day-0 antibody levels) among
vaccinees belonging to the five pentile groups based on
Day-0 antibody levels. Irrespective of the pre-vaccination
antibody level, vaccinees showed considerable variation in
post-vaccination levels or antibody response (see also
Supplementary Figure S1). The correlation between pre-
and post-vaccination antibody levels was low (0.188), but
significant (P \ 0.0005). Among the vaccinees, the
observed differences in the logAR (Fig. 1) could not be
explained by variation in age (P = 0.915), or by gender
(P = 0.100) or religious group (P = 0.302) differences
(Table 2) of the vaccinees. Therefore, we did not stratify
the vaccinees by age, gender or religious group for further
statistical analyses.
Association analysis
After data-curation, data were available on 984 individuals
pertaining to 2,040 SNPs in 283 genes. Of these 2,040
SNPs, the difference in the MAFs between Muslim and
Hindu vaccinees was not statistically significant at the 5%
level for any locus, after correcting for multiple-testing
(Supplementary Figure S2). Thus, even though the vacci-
nees belonged to two maritally isolated religious groups,
there was no genetic stratification or sub-structuring among
the vaccinees. The vaccinees were randomly grouped into
two half-samples; the demographic characteristics of the
vaccinees in these two half-samples were similar and sta-
tistically non-significant (Supplementary Table S2 and
Supplementary Figure S3). Vaccinees belonging to each
half-sample were grouped into 5 pentile groups based on
their AR values; that is, groups defined on the basis of AR
values sorted in ascending order, with each group com-
prising approximately 20% of the total sample. The mean
values of AR among vaccinees belonging to the pentile
groups within half-samples are presented in Table 4.
Between the two half-samples, while the mean values of
AR were not statistically significant for the first three
pentile groups, there were significant differences for the
fourth and fifth pentile groups. These differences arose
from a few individuals who showed high AR in either of
the two half-samples (Supplementary Figure S3), as is
evident from the large standard deviations of AR for these
two pentile groups. While the increase in mean AR from
the first to the third pentile groups is gradual, there is a
sharp increase from third to the fourth pentile group and
also from the fourth to the fifth pentile group. The mean
values of logAR and the MAF for each locus were com-
puted for vaccinees belonging to each pentile group within
Table 3 Ranges and
descriptive statistics of pre- and
post-vaccination levels and
antibody response (AR) among
vaccinees belonging to the five












1 (n = 196) Day-0 0.026 0.014 0.000 0.050
Day-28 7.218 10.065 0.045 68.173
AR 7.193 10.064 0.031 68.136
2 (n = 197) Day-0 0.081 0.020 0.050 0.120
Day-28 21.637 56.840 0.108 691.270
AR 21.556 56.839 0.056 691.211
3 (n = 197) Day-0 0.210 0.060 0.121 0.328
Day-28 40.696 66.614 0.201 514.707
AR 40.486 66.604 0.067 514.521
4 (n = 197) Day-0 0.607 0.208 0.329 1.079
Day-28 74.254 96.472 0.698 717.317
AR 73.647 96.440 0.294 716.404
5 (n = 197) Day-0 6.891 23.264 1.084 293.561
Day-28 205.719 234.984 2.769 1,777.819
AR 198.827 234.098 0.341 1,775.567
Table 4 Mean ± SD antibody response (EU/ml) among individuals belonging to various pentile classes
Half-sample Pentile class (n in each half-sample)
1 (n = 98) 2 (n = 98) 3 (n = 98) 4 (n = 98) 5 (n = 100)
1 1.28 ± 1.00 6.50 ± 1.97 17.11 ± 4.46 63.80 ± 26.66 308.44 ± 252.31
2 1.39 ± 0.97 6.49 ± 2.24 18.08 ± 4.92 47.95 ± 12.52 205.31 ± 160.59
P-value 0.450 0.983 0.150 \0.0009 0.001
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each half-sample. The differences in logAR between con-
secutive pentile groups were statistically significant, within
each half-sample and for the total sample. The differences
in MAFs between half-samples for the 5 pentile groups are
presented in Supplementary Figure S4; none of the dif-
ferences, corrected for multiple-testing, was statistically
significant at the 5% level. To partially circumvent the
statistical problems associated with multiple-testing, a
subset of 469 (out of 2,040) ‘highly informative and min-
imally associated’ SNPs was chosen, with at least one SNP
in each of the 283 genes (see Materials and Methods sec-
tion for further details), for an initial association analysis.
The correlation coefficient (r) between MAF and mean
logAR of vaccinees belonging to the pentile groups of half-
sample 1 was computed for each of the 469 loci selected
for the association analysis. Of these 469 SNPs, only 54
(11.5%) SNPs in 43 genes showed significant correlation
(P-values were estimated by data-permutation), at the 5%
level (using multiple-testing correction by FDR method),
between MAF and mean logAR of vaccinees belonging to
the pentile groups (Table 5).
Cross-validation analysis
The inference that 54 SNPs were significantly associated
with AR was cross-validated using the data on vaccinees
belonging to half-sample 2—in which, as expected, the
demographic characteristics were similar to those of half-
sample 1(Supplementary Table S2 and Supplementary
Figure S3). The same procedure of assessing the signifi-
cance of relationship between logAR and MAF was used
for each of the 54 SNPs considered for cross-validation. Of
these 54 SNPs, significant association was found only for 8
SNPs—all intronic—in 7 genes (Table 6). Figure 3 shows
that there is a near monotonic increase (for 6 SNPs) or
decrease (for 2 SNPs) of MAF with increasing AR.
Table 5 List of 54 SNPs in 43 genes, along with the corresponding correlation coefficient between minor allele frequency and antibody response,
that showed significant association with antibody response in half-sample 1
Chromosome
no.




Gene SNP rs # Corr. coeff.
(r)
1 TNFRSF8 12736809 -0.94 4 IRF2 12512614 -0.96
1 TNFRSF1B 505844 -0.97 6 BAT2 2736172 -0.91
1 IL12RB2 7555183 -0.99 6 HLA-DOB 2859579 -0.99
1 TGFBR3 1017956 -0.94 6 IL22RA2 13197049 0.92
1 XCL1 6700487 0.91 6 CCR6 1571878 -0.96
1 PTGS2 2745557 0.93 8 DEFB1 2978873 0.98
1 IRF6 2073486 -0.93 8 DEFB1 2977772 0.91
1 NLRP3 12565738 -0.92 8 IKBKB 3747811 -0.95
1 NLRP3 10754558 0.98 9 PAX5 7031673 -0.91
2 IL1R2 13022757 -0.93 10 IL2RA 10905668 0.98
2 IL1R2 4850993 -0.95 10 ITGB1 10827164 -0.95
2 IL1R2 3218848 0.98 10 CXCL12 10900030 0.96
2 IL1R2 2110562 -0.92 10 MAPK8 12358297 -0.95
2 IL1RL1 10208293 0.95 10 CHUK 2230804 -0.91
2 IL18R1 1362348 0.92 11 CD59 3181274 -0.94
2 CTLA4 231779 -0.99 11 CD44 112762 -0.97
3 IL5RA 2290610 -0.98 11 IL10RA 4252306 0.93
3 CMTM8 4132830 -0.96 11 TIRAP 8177352 0.98
3 CMTM7 17029530 -0.97 13 IL17D 1888001 0.94
3 CD80 491407 -1.00 13 TNFRSF19 7338328 -0.98
3 CD80 2228017 -0.97 16 IL4R 4787423 0.96
3 CD80 2222631 -0.93 17 CSF3 2227321 -0.95
3 CD80 16829988 -0.99 17 MAP2K6 12946388 -0.95
3 CD86 2681411 0.97 21 ITGB2 235326 0.99
3 CD86 17203439 0.95 22 MAPK1 743409 -0.93
4 TLR1 5743572 0.93 22 MAPK1 2283792 -0.98
4 CXCL13 171388 -0.94 22 MAPK1 3788332 -0.94
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Significance of the other assayed SNPs in genes
showing cross-validated association
To avoid vagaries of multiple-testing, for the association
analysis we selected a subset of assayed SNPs that were not
in strong LD, and identified 8 associated SNPs in 7 genes
(Table 6). We next sought to examine whether any of the
remaining assayed SNPs in these 7 genes also showed
significant association. In the cross-validated gene, CTLA4,
only one SNP was selected for genotype assay, since the
size of the gene is small. In the remaining 6 genes
(Table 6), 100 SNPs were assayed (Table S1), of which 7
were found to be significantly associated with AR and were
cross-validated. Among the additional 93 assayed SNPs in
these 6 genes, 8 showed significant association (Table 6).
These 8 SNPs were also intronic. Quantitative trait (anti-
body response) association analysis with genotypes was
performed for these 16 SNPs; that is, we tested the null
hypothesis that the mean values of logAR among vaccinees
belonging to the three genotypes in the complete data set
(half samples 1 and 2 pooled) were equal. This was carried
out by ANOVA using PLINK (http://www.pngu.mgh.
harvard.edu/*purcell/plink/); all differences were found
to be significant (Table 6) at the 5% level, implying that
mean antibody responses were significantly different
among genotypes.
Haplotype analysis
With the exception of CTLA4, for each of the remaining 6
genes (IL1RL1, CD86, TLR1, DEFB1, MAPK8 and IL17D)
multiple SNPs were assayed, but were not included in the
initial analyses to reduce the number of tests. In these 6
genes, we carried out association analyses with all the
assayed SNPs, and found some of these additional SNPs to
be significantly associated with AR. The additional SNPs
that were significantly associated belonged to 3 genes—
IL1RL1, TLR1 and DEFB1 (Table 6). For these 3 genes in
which multiple SNPs showed significant association with
antibody response, we estimated the frequency of the
haplotype comprising minor alleles at the SNP loci that
were found to be significantly associated (Table 6). For
each of these genes, the signs of the correlation coefficient
between MAF and mean logAR of pentile groups for all
SNPs that were significantly associated were identical (data
not shown). We then estimated the strength of association
between the frequencies of these haplotypes and mean
logAR of vaccinees belonging to the pentile groups using
the total sample (n = 984). Essentially, the nature of and
strength (significant at 5% level) of relationship remained
unaltered (Fig. 4) from that found in the cross-validation
analysis (Fig. 3). Thus, haplotypes based on SNPs in these
genes also showed significant association with AR.
Discussion
Salmonella typhi, that causes typhoid fever, is encapsulated
by a polysaccharide (PS), Vi PS. The expression of Vi PS
correlates with virulence and resistance to nonoxidative
killing and phagocytosis (Looney and Steigbigel 1986).
Infection with encapsulated bacteria can be prevented by
vaccination with capsular polysaccharides. A Vi PS vac-
cine for typhoid is marketed and used in many countries,
including India. Since the transmission of the typhoid
pathogen is through the oral-fecal route, typically the areas
of endemicity of typhoid are also areas where there is low
level of personal and public hygiene. Although it is in such
areas where a vaccination program against typhoid is likely
to have a major public-health impact, residents of such
areas are often exposed to S. typhi and other co-infections
prior to vaccination. Indeed, several studies have reported
that 19–58% percent of subjects that live in endemic areas
involved in Vi polysaccharide vaccine studies develop
protective levels (1 lg/ml) of anti-Vi antibodies without
vaccination (Klugman et al. 1996; Keddy et al. 1999;
Panchanathan et al. 2001). These observations suggest that
natural, environmental exposure to S. typhi has the poten-
tial to induce protective levels of serum, anti-Vi antibodies.
Post-vaccination immune response is likely to be affected
by prior exposure. Participants in this study were chosen
from a high-risk area for typhoid infection. Using appro-
priate criteria, we excluded individuals who may have been
infected with S. typhi at least a year prior to their recruit-
ment in this study, thereby minimizing, to the extent fea-
sible, the confounding effect of immune response due to
prior exposure with that due to vaccination. Our data have
revealed that post-vaccination antibody levels do not
strongly correlate with pre-vaccination levels. This indi-
cates that the vaccine can induce a strong antibody
response even if a vaccinee has a high pre-vaccination level
of antibody and the vice versa.
Immune response to polysaccharide antigens is quali-
tatively different from that to protein antigens. Typically, it
is T-cell independent. T-cell independent antigens are not
consistently immunogenic in children \2 years of age
(Chelvarajan et al. 2005). The Vi polysaccharide vaccine
represents a T-independent antigen that does not generate
antigen-specific CD4? T cell help. Without CD4? T cell
help, long-term memory B cells are not generated. This
explains the need to revaccinate with the Vi polysaccharide
vaccine every 2–3 years (Whitaker et al. 2009). However,
T-cell-independent type 2 (TI-2) antigens, such as Vi PS,
can also stimulate the mature B cells to induce antibody
production through non-cognate T-cells (Obukhanych and
Nussenzweig 2006) and antibody response to Vi PS vac-
cine has been shown to be correlated with the number of
CD4? T lymphocytes (Kroon et al. 1999).
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Despite their T-cell independent nature, some polysac-
charide antigens have been reported to activate dendritic
cells and other cell types. When dendritic cells were treated
with the polysaccharide from Ganoderma lucidum there
was enhanced cell surface expression of CD80, CD86,
CD83, CD40, CD54, and HLA-DR (Kroon et al. 1999). It
is also known that blood dendritic cells interact with
marginal zone (MZ) B cells to initiate TI-2 immune
responses as polysaccharide antigens localize preferentially
to these (MZ) B cells found in spleen (Achtman et al. 2009;
Klouwenberg and Bont 2008). The splenic marginal zone
(MZ) has been implicated as a source of circulating IgM
memory B cells (Kreutzmann et al. 2003). These findings
reveal a larger role for polysaccharides in immune recog-
nition than currently appreciated.
Inter-individual variability in immune response to pep-
tide vaccines has been documented and a number of
polymorphic loci in genes related to both innate and
adaptive immune systems have been found to be associated
with antibody response to vaccines (Sur et al. 2009).
However, little is known about genomics of immune
response for polysaccharide vaccines. To our knowledge,
this is the first large-scale study—involving a large number
of vaccinated individuals (*1,000) and a large number of
polymorphic loci ([2,000)—on genomics of immune
response to a polysaccharide vaccine to prevent S. typhi
infection. Our strategy for data analyses was chosen to
minimize the possibility of false positive discovery and,
with a minimal loss of statistical power, enabled internal
cross-validation of results through a half-sample analytical
design.
Of the 283 genes considered as candidates for this study
of immune response, we have found 16 SNPs in 7 genes to
show significant allelic, genotypic and haplotypic associ-
ations with immune response to the Vi PS vaccine. These 7
genes are b-defensin 1 (DEFB1) with 7 associated SNPs;
toll-like receptor 1 (TLR1) and interleukin 1 receptor-like 1
(IL1RL1) each with 2 associated SNPs; cytotoxic T-lym-
phocyte-associated antigen 4 (CTLA4), mitogen-activated
protein kinase 8 (MAPK8), cluster of differentiation 86—a
molecule expressed on antigen-presenting cells that pro-
vide costimulatory signals necessary for T cell activation
Table 6 Details of 8 SNPs in 7 Genes that showed significant cross-validated association with antibody response, and of other assayed SNPs in



















rs # nt Position SNP location within
gene (mRNA transcript
no. in NCBI database)
IL1RL1 2 13 3 4142132b 102303914 Intron 1 (NM_016232.4) 0.96 0.94 0.011
1997466b 102317899 Intron 1 (NM_016232.4) 0.91 0.94 0.016
10208293c 102332742 Intron 10
(NM_016232.4)
0.95 0.91 0.002
CTLA4 2 1 1 231779 c 204442732 Intron 1 (NM_005214.3) -0.99 -0.93 0.028
CD86 3 17 1 17203439c 123278196 Intron 1 (NM_175862.3) 0.95 0.97 0.016
TLR1 4 24 2 55815313b 38481645 Intron 2 (NM_003263.3) 0.95 0.94 0.022
5743572c 38481786 Intron 2 (NM_003263.3) 0.98 0.93 0.050
DEFB1 8 33 7 2978873c 6717373 Intron 1 (NM_005218.3) 0.98 0.98 0.016
2977780b 6717513 Intron 1 (NM_005218.3) 0.95 0.95 0.018
2980928b 6717829 Intron 1 (NM_005218.3) 0.95 0.95 0.018
2978872b 6718140 Intron 1 (NM_005218.3) 0.93 0.98 0.008
2951854b 6718836 Intron 1 (NM_005218.3) 0.92 0.94 0.028
2980923b 6720467 Intron 1 (NM_005218.3) 0.95 0.93 0.015
2977772c 6720606 Intron 1 (NM_005218.3) 0.91 0.94 0.013
MAPK8 10 7 1 10857564c 49282578 Intron 1 (NM_002750.2) -0.95 -0.96 0.030
IL17D 13 6 1 1888001c 20183906 Intron 2 (NM_138284.1) 0.94 0.91 0.018
a Including assayed SNPs in 2 kb regions upstream and downstream of the gene
b Association significant in both Half-samples (was not included in the initial analysis of 469 SNPs)
c Association found to be significant in Half-Sample 1 and cross-validated in Half-Sample 2 (i.e., included in the initial analysis of 469 SNPs)
d P-values corresponding to these correlation coefficients are all \0.005, and with FDR \ 0.05
e Essentially each P-value corresponds to a test of equality of mean values of logAR among individuals belonging to the three genotypes at the
locus under consideration
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and survival (CD86) and interleukin 17D (IL17D) each
with 1 associated SNP.
Though the role of T lymphocytes in the regulation of
the antibody production to PS is obscure, anti-PS response
involves non-cognate activation of TCR-nonspecific T
cells by implicating a role for endogenous CD40-CD40L
interactions in the human antibody response (Snapper et al.
2001). It is known that B7 family of co-stimulatory mol-
ecules, CD86 along with CD80, present on the antigen-
presenting cells (APCs), interact with CD28/CTLA4
receptors on T cells to provide major non-cognate co-
stimulatory signals (Khan et al. 2007). Therefore, it is not
surprising that CD86 and CTLA4 genes showed significant
association with immune response to Vi PS vaccine in the
present study, indicative of a non-cognate T-cell depen-
dence. TLR1 showed association with the host response to
the vaccine. Downregulation of TLR-mediated immune
responses through diminished TLR-mediated cell signaling
or expression is an important immune evasion mechanism
in some bacterial pathogens (Alvarez 2005; Babu et al.
2009). Data from experiments with human colonic tissue
explants indicate that the Vi antigen reduces TLR-mediated
IL-8 signaling, thereby evading TLR-mediated host
response triggering neutrophil infiltration in the intestinal
mucosa (Wilson et al. 2008). However, it is not clear if Vi
polysaccharide is recognized by TLR1 or if the TLR1 gene
influences host responses to co-infections that then indi-
rectly influences host response to vaccination with Vi PS.
All toll-like receptors have a toll-interleukin 1 domain that
is responsible for signal transduction; IL1RL1—a gene that
we have found to be significantly associated with AR
induced by the PS vaccine—participates in this signaling.
Fig. 3 Increase/decrease in
minor allele frequency (MAF)
from the lowest to the highest
pentile group of antibody
response (open circles pertain to
half-sample 1, open squares to
half-sample 2 and solid
triangles to the complete data)
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MAP kinases are involved in a wide variety of cellular
processes such as proliferation, differentiation, transcrip-
tion regulation and development; therefore, the association
of a SNP in MAPK8 with antibody response is not unex-
pected. There are reports demonstrating that the MAP
kinase pathway may be one of the targets that is modulated
by Vi to dampen early inflammatory responses in Vi
polysaccharide treated intestinal epithelial cells (Caco-2;
Sharma and Qadri 2004). This may explain why MAPK8
was found to be associated with Vi polysaccharide anti-
body response. The involvement of a MAP kinase and
IL17D, that stimulates the production of other cytokines,
can result in pro-inflammatory signals that can induce
upregulation of DEFB1 (O’Neil et al. 1999). We have
found multiple SNPs in DEFB1 to be significantly asso-
ciated with Vi polysaccharide vaccine response. Thus, the
overall picture that emerges from our findings is that
polymorphisms in genes involved in polysaccharide rec-
ognition, signal transduction, inhibition of T-cell prolifer-
ation, pro-inflammatory signaling and eventual production
of antimicrobial peptides are associated with antibody
response to the Vi polysaccharide vaccine for typhoid.
However, just as co-infection with parasites (Harris et al.
2009) or other infectious agents (Sugata et al. 2008; Lin
et al. 2006) can influence immunological response to a
pathogen, it is possible, that antibody response to vacci-
nation with Vi polysaccharide may be affected by co-
infections or prior exposure. While it is difficult to rule out
the involvement of other genes in modulation of immune
response to the Vi polysaccharide vaccine, the 7 genes that
we have found to be associated with host antibody response
to the polysaccharide vaccine provide a foundation for
elucidating the functional mechanism of the products of
these genes in host response to the polysaccharide vaccine.
However, we emphasize that the evaluation of genes that
influence host antibody response to the Vi polysaccharide
vaccine is complicated by the living conditions (i.e.,
environment) of the study participants and the lack of
knowledge regarding the exact microbial exposure (S. typhi
or other infectious agents) of each study participant. It is
desirable that similar studies be performed on participants
residing in hygienic areas that lack natural exposure to S.
typhi, and with access to good quality water and hygienic
sewer services, although residents of such areas are unli-
kely to require vaccination for typhoid.
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